ORKA · Company research
Oruka Therapeutics, Inc. Common Stock (ORKA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
24records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Avoiding Lag: Real-Time Signals in (ORKA) Movement - Stock Traders Daily | Avoiding Lag: Real-Time Signals in (ORKA) Movement Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 18, 2026 | neutral | 0 | 0.6 |
| Oruka Therapeutics: The Psoriasis Market Becoming A Barbell, And ORKA-001 Owns The Far End - Seeking Alpha | Oruka Therapeutics: The Psoriasis Market Becoming A Barbell, And ORKA-001 Owns The Far End Seeking Alpha | View source ↗ | Seeking Alpha | Oct 18, 2026 | neutral | 0 | 0.6 |
| ORKA Oct 2026 70.000 put (ORKA261016P00070000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ORKA Oct 2026 70.000 put (ORKA261016P00070000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| ORKA Dec 2027 30.000 put (ORKA271217P00030000) Interactive Stock Chart - Yahoo! Finance Canada | ORKA Dec 2027 30.000 put (ORKA271217P00030000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| ORKA Dec 2027 30.000 call (ORKA271217C00030000) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada | ORKA Dec 2027 30.000 call (ORKA271217C00030000) Interactive Stock Chart - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| ORKA Dec 2027 30.000 call (ORKA271217C00030000) Stock Historical Prices & Data - Yahoo Finance - Yahoo! Finance Canada | ORKA Dec 2027 30.000 call (ORKA271217C00030000) Stock Historical Prices & Data - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| ORKA Dec 2027 100.000 put (ORKA271217P00100000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ORKA Dec 2027 100.000 put (ORKA271217P00100000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| ORKA Dec 2027 165.000 call (ORKA271217C00165000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ORKA Dec 2027 165.000 call (ORKA271217C00165000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| A proposed 21,000-share sale at Oruka Therapeutics (ORKA) involves officer Joana Goncalves. - Stock Titan | A proposed 21,000-share sale at Oruka Therapeutics (ORKA) involves officer Joana Goncalves. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead | Revolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history. | View source ↗ | The Motley Fool | Oct 15, 2026 | neutral | -0.077 | 1 |
| These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead | Revolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history. | View source ↗ | The Motley Fool | Oct 15, 2026 | neutral | -0.077 | 1 |
| An officer proposes selling 9,999 Oruka Therapeutics (ORKA) shares acquired through stock options. - Stock Titan | An officer proposes selling 9,999 Oruka Therapeutics (ORKA) shares acquired through stock options. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Piper Sandler Keeps Their Buy Rating on Oruka Therapeutics (ORKA) - The Globe and Mail | Piper Sandler Keeps Their Buy Rating on Oruka Therapeutics (ORKA) The Globe and Mail | View source ↗ | The Globe and Mail | Oct 8, 2026 | neutral | 0 | 0.6 |
| (ORKA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily | (ORKA) as a Liquidity Pulse for Institutional Tactics Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 8, 2026 | neutral | 0 | 0.6 |
| 25,000 shares from a stock-option exercise are proposed for sale at Oruka Therapeutics (NASDAQ: ORKA). - Stock Titan | 25,000 shares from a stock-option exercise are proposed for sale at Oruka Therapeutics (NASDAQ: ORKA). Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| How Investors Are Reacting To Oruka Therapeutics (ORKA) Positive Psoriasis Trial Results - Simply Wall Street | How Investors Are Reacting To Oruka Therapeutics (ORKA) Positive Psoriasis Trial Results Simply Wall Street | View source ↗ | Simply Wall Street | Oct 1, 2026 | neutral | 0 | 0.6 |
| ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data - Yahoo Finance | ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data Yahoo Finance | View source ↗ | Yahoo Finance | Sep 24, 2026 | neutral | 0 | 0.6 |
| What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders - Yahoo Finance | What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders Yahoo Finance | View source ↗ | Yahoo Finance | Sep 23, 2026 | neutral | 0 | 0.6 |
| In a psoriasis trial, 71% had clear skin six months after their last dose - Stock Titan | In a psoriasis trial, 71% had clear skin six months after their last dose Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know - Zacks Investment Research | ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know Zacks Investment Research | View source ↗ | Zacks Investment Research | Aug 28, 2026 | neutral | 0 | 0.6 |
| ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know - Yahoo Finance | ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Aug 28, 2026 | neutral | 0 | 0.6 |
| ORKA Stock Climbs As Traders Track Strong Cash Runway - StocksToTrade | ORKA Stock Climbs As Traders Track Strong Cash Runway StocksToTrade | View source ↗ | StocksToTrade | Jul 17, 2026 | neutral | 0 | 0.6 |
| Oruka Therapeutics Rises as Investors Focus on Pipeline Data Setup | ORKA Stock News - Quiver Quantitative | Oruka Therapeutics Rises as Investors Focus on Pipeline Data Setup | ORKA Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 17, 2026 | neutral | 0 | 0.6 |
| ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits | ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% Stocktwits | View source ↗ | Stocktwits | Apr 27, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.